野村:料中生製藥(1177.HK)盈利增速將加快 目標價14.5港元
野村發表研究報告指,中國生物製藥(1177.HK)於今年首季銷售及純利按年增長分別為0.2%及0.6%,符合市場預期,亦料未來受創新產品及仿製藥的銷量帶動,其盈利增長速度將於2021-2022年加快,維持14.5港元目標價,重申買入投資評級。
野村表示,公司旗下業務發展進度良好,能達成全年目標,於上月已獲得15個新藥簡略申請批准,料公司的抗PD-1單抗藥物安尼可可於明年下半年獲得新藥上市申請(NDA),亦指於2020-2021年期間每年將提交3-4個創新產品的NDA。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.